SK-MEL-26 is one of a series of melanoma cell lines established from patient-derived tumor samples. This cell line expresses mutant B-Raf (V600E) and wildtype N-Ras. SK-MEL-26 cells form tumors in immunocompromised mice.
This cell line was established in 1975 from a subcutaneous malignant melanoma on the right leg of a 54-year-old Caucasian female.
- Lloyd J. Old, MD, former William E. Snee Chair in Cancer Immunology, Memorial Sloan Kettering; former Director, New York Branch, Ludwig Institute for Cancer Research
- Toshitada Takahashi, MD, formerly at Sloan Kettering Institute, Memorial Sloan Kettering
- Fogh J et al. (1977) One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. Journal of the National Cancer Institute 59: 221-226 (PubMed ID: 327080)
- Gomi K et al. (1984) Antitumor effect of human recombinant interferon-beta against human melanomas transplanted into nude mice. Journal of Pharmacobiodynamics 7: 951-961 (PubMed ID: 6533284)
- Fujino M et al. (1999) Effects of protein kinase inhibitors on radiation-induced WAF1 accumulation in human cultured melanoma cells. British Journal of Dermatology 141: 652-657 (PubMed ID: 10583112)
- Xing F et al. (2012) Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E) BRAF. Oncogene 31(4): 446-457 (PubMed ID: 21725359)
This cell line may be licensed nonexclusively for research or commercial purposes.
- For licensing requests: Alexandra Buga, MBA, Business Development Analyst, Office of Technology Development, MSK, 646-888-1078, firstname.lastname@example.org
- For non-licensing requests from academic-research institutions: Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, email@example.com